In this episode, Dr. Morice and Dr. Pritt talk about what the recent surge in COVID-19 cases means and how we can all do our part to help prevent further spread.

In this episode, Dr. Morice and Dr. Pritt, discuss the rise in cases of COVID-19 caused by the coronavirus delta variant in the U.S., especially in areas with low vaccination rates.

Bobbi Pritt, M.D., and William Morice II, M.D., Ph.D., discuss how to prevent, diagnose, and treat vector-borne diseases — illness you get from blood-feeding anthropods like ticks and mosquitos — that are more common during the summertime.

Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac disease or inflammatory bowel disease. Performed on tissue sample biopsies during upper endoscopy, the activity panel is the gold standard test for detecting disaccharidase deficiencies.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D. discuss a recent report to Congress that outlined potential laboratory fee reimbursement changes, and what that could mean for labs going forward.

Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by testicular cancer-associated paraneoplastic encephalitis.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update.

Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and insight on disease expression.

In this episode, William Morice II, M.D., Ph.D., explains his dual leadership role at Mayo Clinic and discusses how engaging in the business of a reference laboratory informs his work within academic medicine.

Bobbi Pritt, M.D., discusses how Mayo Clinic Labs’ updated PCR assay for West Nile virus provides increased sensitivity to detect virus RNA in multiple sources, identifies two virus lineages, and confirms diagnosis.

Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, hosts this episode of the "Answers From the Lab" podcast. He’s joined by Gianluca Pettiti, senior vice president and president of specialty diagnostics at Thermo Fisher Scientific to discuss their organizations’ collaboration and its value for patients.